Discover
etrasimod (APD334) / ArenaEtrasimod clinical trial estimate: Data from P2b/3 CULTIVATE trial (NCT04173273) for Crohn’s disease in H2 2021 (SVB Leerink) - Jan 6, 2020 - A subscription to Thomson ONE is required to gain full access to report 68502627; Page no: 72; REPORT TITLE: "2020 outlook for investing in healthcare”; AUTHOR: Sullivan, John, et al; DATE: 12/16/2019etrasimod (APD334) / ArenaEtrasimod clinical trial estimate: Data from P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis at year end 2021 (SVB Leerink) - Jan 6, 2020 - Etrasimod clinical trial estimate: Data from P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis at year end 2021Myoconda (clarithromycin/clofazimine/rifabutin) / RedHillMAPUS: Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (clinicaltrials.gov) - Jan 2, 2020 - P3; N=331; Completed; Sponsor: RedHill Biopharma Limited; Active, not recruiting --> Completed; Trial completion date: Apr 2019 --> Aug 2019Stelara (ustekinumab) / J&JStelara patent expiry: January 2024 in EU (Barclays) - Jan 2, 2020 - A subscription to Thomson ONE is required to gain full access to report 68519497; Page no: 8; REPORT TITLE: "Johnson & Johnson: Last minute gift idea? JNJ; Upgrade to overweight”; AUTHOR: Stewart, Kristen, et al; DATE: 12/19/2019Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKAXifaxan patent protection: Until 2031 for soluble solid dispersion tablets (Guggenheim) - Dec 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68502576; Page no: 4; REPORT TITLE: "Bausch Health Companies Ltd- BHC (Buy) - Hepatic encephalopathy (HE) deep dive ahead of phase 2 data”; AUTHOR: Research Department; DATE: 12/16/2019Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&JSimponi patent expiry: April 2025 in EU and February 2024 in US (Barclays) - Jan 2, 2020 - A subscription to Thomson ONE is required to gain full access to report 68519497; Page no: 8; REPORT TITLE: "Johnson & Johnson: Last minute gift idea? JNJ; Upgrade to overweight”; AUTHOR: Stewart, Kristen, et al; DATE: 12/19/2019filgotinib (GLPG0634) / GileadFilgotinib WW sales projection: $6.7B in 2030 (Morgan Stanley) - Jan 3, 2020 - A subscription to Thomson ONE is required to gain full access to report 68506973; Page no: 207; REPORT TITLE: "Biotechnology: 2020 outlook: Still a stockpickers' world, but macro pressures receding”; AUTHOR: Harrison, Matthew, et al; DATE: 12/17/2019Humira (adalimumab) / Eisai, AbbViePfizer, AbbVie and Gilead among drugmakers boosting prices to start 2020 (BioPharma Dive) - Jan 2, 2020 - "Some of the largest pharmaceutical and biotech companies started 2020 by increasing U.S. list prices for a range of top-selling medications, despite intense political scrutiny on the industry and its pricing practices...AbbVie raised the list price of Humira (adalimumab), the world's best-selling drug, by 7.4%, according to Raymond."Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKAXifaxan patent protection: Until 2027 (Cowen & Co) - Dec 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68468883; Page no: 1; REPORT TITLE: "Bausch Health Companies Ltd- Best ideas for 2020: Continued execution should generate significant value”; AUTHOR: Cacciatore, Ken,et al; DATE: 12/09/2019Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKAXifaxan sales projection: $2.3B by 2028 (Guggenheim) - Dec 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68502576; Page no: 2; REPORT TITLE: "Bausch Health Companies Ltd- BHC (Buy) - Hepatic encephalopathy (HE) deep dive ahead of phase 2 data”; AUTHOR: Research Department; DATE: 12/16/2019
